Literature DB >> 26879362

Effect of Rheumatoid Arthritis on Longterm Sickness Absence in 1994-2011: A Danish Cohort Study.

Sofie Mandrup Hansen1, Merete Lund Hetland2, Jacob Pedersen2, Mikkel Østergaard2, Tine Steen Rubak2, Jakob Bue Bjorner2.   

Abstract

OBJECTIVE: By linkage of national registries, we investigated the risk of longterm sickness absence (LTSA) ≥ 3 weeks in a large cohort of Danish patients with rheumatoid arthritis (RA) and non-patients. The study aimed to (1) estimate the risk of LTSA for patients with RA compared with the general population, (2) examine whether the risk of LTSA has changed in recent years, and (3) evaluate the effect of other risk factors for LTSA (e.g., physical work demands, age, sex, education, and psychiatric and somatic comorbidities).
METHODS: A total of 6677 patients with RA aged 18-59 years in the years 1994-2011 were identified in registries and compared with 56,955 controls from the general population matched by age, sex, and city size. The risk of LTSA was analyzed using Cox proportional hazards models with late entry, controlling for other risk factors and assuming separate risks in the first year after diagnosis and the following years.
RESULTS: Compared with the general population, patients with RA had increased risk of LTSA in the first year after diagnosis (HR 5.4 during 1994-1999, 95% CI 4.2-6.8) and in following years (HR 2.4, 95% CI 2.1-2.8). For established RA (> 1 yr after diagnosis), the excess was 20% lower in 2006-2011 (HR 1.9, 95% CI 1.7-2.2) compared with 1994-1999 (p < 0.001). For patients with RA and controls, older age, shorter education, a physically demanding job, and somatic and/or psychiatric comorbidities increased the risk of LTSA.
CONCLUSION: While improvements were observed from 1994-1999 to 2006-2011, patients with RA have significant increased risk of LTSA, in particular in the first year after diagnosis.

Entities:  

Keywords:  COHORT STUDY; COX PROPORTIONAL HAZARDS MODEL; EMPLOYEE WORK LOAD; REGISTRY; RHEUMATOID ARTHRITIS; SICK LEAVE

Mesh:

Year:  2016        PMID: 26879362     DOI: 10.3899/jrheum.150801

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Worklife expectancy in a cohort of Danish employees aged 55-65 years - comparing a multi-state Cox proportional hazard approach with conventional multi-state life tables.

Authors:  Jacob Pedersen; Jakob Bue Bjorner
Journal:  BMC Public Health       Date:  2017-11-15       Impact factor: 3.295

2.  Work Ability and Employment in Rheumatoid Arthritis: A Cross-Sectional Study on the Role of Muscle Strength and Lower Extremity Function.

Authors:  Carolin Berner; Sandra Haider; Igor Grabovac; Thomas Lamprecht; Karl Heinrich Fenzl; Ludwig Erlacher; Michael Quittan; Thomas Ernst Dorner
Journal:  Int J Rheumatol       Date:  2018-08-01

3.  Deployment experiences and mental health problems as predictors of post-deployment unemployment length: a prospective, register-based study among Danish soldiers.

Authors:  Andreas Friis Elrond; Paul Maurice Conway; Søren Bo Andersen; Karen-Inge Karstoft; Mia Sadowa Vedtofte; Jacob Pedersen
Journal:  BMJ Open       Date:  2020-12-07       Impact factor: 2.692

4.  Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider.

Authors:  Mary Lucy Marques; Alessia Alunno; Sofia Ramiro; Polina Putrik; Annelies Boonen; Marieke M Ter Wee; Louise Falzon
Journal:  RMD Open       Date:  2021-02

5.  Long-term sickness absence of 32 chronic conditions: a Danish register-based longitudinal study with up to 17 years of follow-up.

Authors:  Mette Andersen Nexo; Kathrine Carlsen; Jacob Pedersen; Merete Lund Hetland; Torquil Watt; Sofie Mandrup Hansen; Jakob Bue Bjorner
Journal:  BMJ Open       Date:  2018-06-30       Impact factor: 2.692

6.  Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study.

Authors:  Frank Behrens; Hans-Peter Tony; Michaela Koehm; Eva C Schwaneck; Holger Gnann; Gerd Greger; Harald Burkhardt; Marc Schmalzing
Journal:  Clin Rheumatol       Date:  2020-03-23       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.